Compare PXED & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | NEO |
|---|---|---|
| Founded | 1976 | 2001 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Other Consumer Services | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2008 |
| Metric | PXED | NEO |
|---|---|---|
| Price | $33.11 | $14.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $44.29 | $13.38 |
| AVG Volume (30 Days) | 82.1K | ★ 2.9M |
| Earning Date | 04-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | $10.63 |
| Revenue Next Year | $4.49 | $9.73 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $4.72 |
| 52 Week High | $38.19 | $13.88 |
| Indicator | PXED | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 78.61 |
| Support Level | $28.40 | $11.49 |
| Resistance Level | $33.05 | N/A |
| Average True Range (ATR) | 1.34 | 0.65 |
| MACD | 0.07 | 0.24 |
| Stochastic Oscillator | 91.44 | 94.98 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.